Please assess the completion status of the following clinical trial:

Trial Title: Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female over the age of 18 years~* Diastolic blood pressure (DBP) greater tha 80 mmHg and less than 104 mmHg~* Type II diabetes on diet or oral hypoglycemic agents with a hemoglobin A1C (HbA1C) less than 0.080~* UA ratio albumin:creatinine 2.0 to 25 mg/mmol~Exclusion Criteria:~* DBP \> 104 mmhg~* Woman not surgically sterile or menopausal.~* Premenopausal women whoo are not surgically sterile or who are not practicing acceptable means of birth control and do not agree to submit to periodic pregnancy tests.~* Known or secondary forms of hypertension.~* Intolerance to angiotensin (AT) 1 receptor blockers or angiotensin-converting enzyme (ACE) inhibitors.~* Hepatic or renal dysfunction. Creatinine \> 150 umol or enzymes greater than 2 times upper limit of normal.~* Hemodynamically significant renal artery stenosis, renal artery stenosis on a solitary kidney, post-renal transplant or with only one kidney.~* Uncorrected volume depletion.~* Biliary obstructive disorders.~* NYHA functional class congestive heart failure (CHF) III-IV.~* Coronary heart disease needing pharmacological therapy.~* Stroke within the preceding six months.~* Percutaneous transluminal coronary angioplasty (PTCA) within the preceding three months.~* History of angioedema.~* Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant cardiac arrhythmias as determined by the clinical investigator.~* Second or third degree AV block, left bundle branch block or any clinically relevant conduction abnormality as determined by the clinical investigator.~* Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve.~* Administration of digoxin.~* Patients with a fasting glucose greater than 7.0~* History of drug or alcohol dependency.~* Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, alpha-blockers, beta-blockers, calcium channel antagonists, direct vasodilators that cannot be stopped for the trial.~* Administration of other non-antihypertensive medications known to affect blood pressure (e.g. oral corticosteroids, monoamine oxidase \[MAO\] inhibitors, nitrates) at any time during the trial.~* Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions.~* Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.~* Clinically significant hyperkalemia as defined by serum potassium level greater than 5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less than 3.0 mEq/L.~* Patients receiving any investigational therapy within one month of signing the informed consent form.~* Known hypersensitivity to any component of telmisartan, ramipril or hydrochlorothiazide.~* Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of trial medication.~* Blood donation in the preceding 1 month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues